329 related articles for article (PubMed ID: 20869410)
1. Liposomal pravastatin inhibits tumor growth by targeting cancer-related inflammation.
Coimbra M; Banciu M; Fens MH; de Smet L; Cabaj M; Metselaar JM; Storm G; Schiffelers RM
J Control Release; 2010 Dec; 148(3):303-10. PubMed ID: 20869410
[TBL] [Abstract][Full Text] [Related]
2. Anti-tumor activity of liposomal glucocorticoids: The relevance of liposome-mediated drug delivery, intratumoral localization and systemic activity.
Kluza E; Yeo SY; Schmid S; van der Schaft DW; Boekhoven RW; Schiffelers RM; Storm G; Strijkers GJ; Nicolay K
J Control Release; 2011 Apr; 151(1):10-7. PubMed ID: 21130819
[TBL] [Abstract][Full Text] [Related]
3. Anti-angiogenic effects of liposomal prednisolone phosphate on B16 melanoma in mice.
Banciu M; Schiffelers RM; Fens MH; Metselaar JM; Storm G
J Control Release; 2006 Jun; 113(1):1-8. PubMed ID: 16707187
[TBL] [Abstract][Full Text] [Related]
4. Targeted delivery of oncogene-selective antisense oligonucleotides in neuroectodermal tumors: therapeutic implications.
Pastorino F; Brignole C; Marimpietri D; Di Paolo D; Zancolli M; Pagnan G; Ponzoni M
Ann N Y Acad Sci; 2004 Dec; 1028():90-103. PubMed ID: 15650235
[TBL] [Abstract][Full Text] [Related]
5. Improved tumor-targeting drug delivery and therapeutic efficacy by cationic liposome modified with truncated bFGF peptide.
Chen X; Wang X; Wang Y; Yang L; Hu J; Xiao W; Fu A; Cai L; Li X; Ye X; Liu Y; Wu W; Shao X; Mao Y; Wei Y; Chen L
J Control Release; 2010 Jul; 145(1):17-25. PubMed ID: 20307599
[TBL] [Abstract][Full Text] [Related]
6. Effect of pravastatin on bleomycin-induced acute lung injury and pulmonary fibrosis.
Kim JW; Rhee CK; Kim TJ; Kim YH; Lee SH; Yoon HK; Kim SC; Lee SY; Kwon SS; Kim KH; Kim YK
Clin Exp Pharmacol Physiol; 2010 Nov; 37(11):1055-63. PubMed ID: 20659133
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of liposomes and hyperthermia in a human tumor xenograft model: importance of triggered drug release.
Kong G; Anyarambhatla G; Petros WP; Braun RD; Colvin OM; Needham D; Dewhirst MW
Cancer Res; 2000 Dec; 60(24):6950-7. PubMed ID: 11156395
[TBL] [Abstract][Full Text] [Related]
8. Systemic delivery of liposomal short-chain ceramide limits solid tumor growth in murine models of breast adenocarcinoma.
Stover TC; Sharma A; Robertson GP; Kester M
Clin Cancer Res; 2005 May; 11(9):3465-74. PubMed ID: 15867249
[TBL] [Abstract][Full Text] [Related]
9. Liposomalization of lactoferrin enhanced its anti-tumoral effects on melanoma cells.
Roseanu A; Florian PE; Moisei M; Sima LE; Evans RW; Trif M
Biometals; 2010 Jun; 23(3):485-92. PubMed ID: 20191307
[TBL] [Abstract][Full Text] [Related]
10. Targeted liposomal c-myc antisense oligodeoxynucleotides induce apoptosis and inhibit tumor growth and metastases in human melanoma models.
Pastorino F; Brignole C; Marimpietri D; Pagnan G; Morando A; Ribatti D; Semple SC; Gambini C; Allen TM; Ponzoni M
Clin Cancer Res; 2003 Oct; 9(12):4595-605. PubMed ID: 14555535
[TBL] [Abstract][Full Text] [Related]
11. Harmine inhibits tumour specific neo-vessel formation by regulating VEGF, MMP, TIMP and pro-inflammatory mediators both in vivo and in vitro.
Hamsa TP; Kuttan G
Eur J Pharmacol; 2010 Dec; 649(1-3):64-73. PubMed ID: 20858484
[TBL] [Abstract][Full Text] [Related]
12. Immune cell-mediated antitumor activities of GD2-targeted liposomal c-myb antisense oligonucleotides containing CpG motifs.
Brignole C; Pastorino F; Marimpietri D; Pagnan G; Pistorio A; Allen TM; Pistoia V; Ponzoni M
J Natl Cancer Inst; 2004 Aug; 96(15):1171-80. PubMed ID: 15292389
[TBL] [Abstract][Full Text] [Related]
13. Liposomal N,N,N-trimethylsphingosine (TMS) as an inhibitor of B16 melanoma cell growth and metastasis with reduced toxicity and enhanced drug efficacy compared to free TMS: cell membrane signaling as a target in cancer therapy III.
Park YS; Hakomori S; Kawa S; Ruan F; Igarashi Y
Cancer Res; 1994 Apr; 54(8):2213-7. PubMed ID: 8174128
[TBL] [Abstract][Full Text] [Related]
14. Silk fibroin mediated delivery of liposomal emodin to breast cancer cells.
Cheema SK; Gobin AS; Rhea R; Lopez-Berestein G; Newman RA; Mathur AB
Int J Pharm; 2007 Aug; 341(1-2):221-9. PubMed ID: 17499461
[TBL] [Abstract][Full Text] [Related]
15. Sequential administration with oxaliplatin-containing PEG-coated cationic liposomes promotes a significant delivery of subsequent dose into murine solid tumor.
Abu Lila AS; Doi Y; Nakamura K; Ishida T; Kiwada H
J Control Release; 2010 Mar; 142(2):167-73. PubMed ID: 19861140
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of macrophage phagocytotic activity by a receptor-targeted polymer vesicle-based drug delivery formulation of pravastatin.
Broz P; Ben-Haim N; Grzelakowski M; Marsch S; Meier W; Hunziker P
J Cardiovasc Pharmacol; 2008 Mar; 51(3):246-52. PubMed ID: 18356688
[TBL] [Abstract][Full Text] [Related]
17. Similar effects of atorvastatin, simvastatin and pravastatin on thrombogenic and inflammatory parameters in patients with hypercholesterolemia.
Joukhadar C; Klein N; Prinz M; Schrolnberger C; Vukovich T; Wolzt M; Schmetterer L; Dorner GT
Thromb Haemost; 2001 Jan; 85(1):47-51. PubMed ID: 11204586
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the anti-inflammatory and anti-proliferation tumoral cells activities of Antrodia camphorata, Cordyceps sinensis, and Cinnamomum osmophloeum bark extracts.
Rao YK; Fang SH; Tzeng YM
J Ethnopharmacol; 2007 Oct; 114(1):78-85. PubMed ID: 17822865
[TBL] [Abstract][Full Text] [Related]
19. Critical factors in the development of tumor-targeted anti-inflammatory nanomedicines.
Coimbra M; Crielaard BJ; Storm G; Schiffelers RM
J Control Release; 2012 Jun; 160(2):232-8. PubMed ID: 22062692
[TBL] [Abstract][Full Text] [Related]
20. Multiple administration of PEG-coated liposomal oxaliplatin enhances its therapeutic efficacy: a possible mechanism and the potential for clinical application.
Abu Lila AS; Eldin NE; Ichihara M; Ishida T; Kiwada H
Int J Pharm; 2012 Nov; 438(1-2):176-83. PubMed ID: 22944302
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
